{"entity":{"id":"nct07004413","kind":"trial","name":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","aka":["FIRE-11"],"tldr":"A phase 3 trial in colorectal cancer, run by Charite University, Berlin, Germany, not yet recruiting.","summary":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients is a phase 3, randomised interventional study registered as NCT07004413 by Charite University, Berlin, Germany, with a registry enrolment figure of 267 participants, started 2026-10-01 and due to reach its primary completion in 2028-10-01. Interventions recorded: FOLFIRI+cetuximab; Guardant360 ctDNA assay. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression-free survival (PFS) on treatment rate at 12 months. Colorectal eligibility wording from the registry: \"Histologically confirmed, UICC stage IV unresectable adenocarcinoma of the colon or rectum\". Sites: Germany. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07004413","url":"https://clinicaltrials.gov/study/NCT07004413"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":["guardant-health","merck-kgaa"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07004413","phase":"3","setting":"Randomized Study to Compare First-line Treatment With Either Continuous or Intermittent Cetuximab Plus FOLFIRI in Patients With RAS/BRAF-wild-type Metastatic Colorectal Cancer (mCRC): AIO-KRK-0524 / FIRE-11","sponsor":"Charite University, Berlin, Germany","enrolled":267,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07004413/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/"},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}